Docetaxel
證據等級: L1 | 預測適應症: 10 個
## 藥師評估報告
Docetaxel：從HER2陽性乳癌到女性乳腺癌
一句話總結
Docetaxel 原本用於治療 HER2 陽性乳癌及轉移性胃癌。 TxGNN 模型預測它可能對**女性乳腺癌 (female breast carcinoma)** 有效， 目前有 **超過50個臨床試驗**和 **多篇文獻**支持這個方向。
快速總覽
| 項目 | 內容 |
|---|---|
| 原適應症 | HER2陽性早期乳癌、轉移性乳癌、轉移性胃癌 |
| 預測新適應症 | 女性乳腺癌、Ewing sarcoma、well-differentiated fetal adenocarcinoma of the lung、small cell lung carcinoma、primary pulmonary lymphoma、botryoid-type embryonal rhabdomyosarcoma of the vagina、pulmonary blastoma、rhabdomyosarcoma (disease)、embryonal extrahepatic bile duct rhabdomyosarcoma、parameningeal embryonal rhabdomyosarcoma |
| TxGNN 預測分數 | 99.90% |
| 證據等級 | L1 |
| 台灣上市 | 已上市 |
| 許可證數 | 多張 |
| 建議決策 | Proceed |
預測適應症詳細分析
1. female breast carcinoma L1 99.90% 主要分析
為什麼這個預測合理？
Docetaxel 屬於 taxane 類抗腫瘤藥物，透過促進微管蛋白聚合並抑制微管解聚來干擾細胞分裂，
導致細胞週期停滯在 G2/M 期。其在乳癌治療中的療效已被廣泛證實，
包括與 trastuzumab、carboplatin 等藥物併用的多種治療方案。
預測其對女性乳腺癌有效具有明確的機轉基礎。
</p>
</details>
此預測基於藥物的作用機轉，與現有臨床證據方向一致。
臨床試驗
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT03879577 | PHASE2 | ACTIVE_NOT_RECRUITING | 53 | Assessing REsponse to Neoadjuvant Taxotere and Trastuzumab in Nigerian Women Wit... |
| NCT00002707 | PHASE3 | COMPLETED | 2411 | A RANDOMIZED TRIAL COMPARING PREOPERATIVE DOXORUBICIN (ADRIAMYCIN)/CYCLOPHOSPHAM... |
| NCT01015963 | N/A | COMPLETED | 69 | A Study of the Docetaxel Pharmacodynamics and Polymorphisms in ABCC2 and SLC01B3... |
| NCT00546364 | PHASE2 | TERMINATED | 62 | IXTEND: A Randomized Phase 2 Study to Evaluate the Combination of Ixabepilone Pl... |
| NCT01293851 | N/A | TERMINATED | 3 | Characterization of the Molecular-Genetic Mechanisms Associated With Chemotherap... |
| NCT00343512 | PHASE2 | TERMINATED | 34 | Pilot Study of Neoadjuvant Dose Dense Docetaxel With Correlative Molecular Studi... |
| NCT00561119 | PHASE3 | COMPLETED | 326 | Phase III, Multicenter, Randomized Trial of Maintenance Versus Observation After... |
| NCT05714553 | PHASE1, PHASE2 | TERMINATED | 19 | A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion ... |
| NCT00014456 | PHASE1 | COMPLETED | 35 | A Dose-Escalation Trial Of The Combination Of Docetaxel, Gemcitabine And Filgras... |
| NCT00963729 | PHASE3 | COMPLETED | 756 | A Neoadjuvant Study of Chemotherapy Versus Endocrine Therapy in Postmenopausal P... |
| NCT00193011 | PHASE3 | COMPLETED | 150 | A Randomized Multicenter Trial Comparing Weekly Docetaxel and CMF in the Adjuvan... |
| NCT00047255 | PHASE3 | COMPLETED | 263 | A Multicenter Phase III Randomized Trial Comparing Docetaxel (Taxotere) and Tras... |
| NCT04975451 | PHASE2 | UNKNOWN | 30 | Neoadjuvant Treatment Anlotinib Combined With Docetaxel and Carboplatin in Tripl... |
| NCT00003565 | PHASE2 | COMPLETED | 109 | A Study of Population Pharmacokinetics of Docetaxel (Taxotere) in Caucasian and ... |
| NCT00104624 | PHASE2 | TERMINATED | 53 | Phase II Trial Assessing the Impact on Instrumental and Daily Living Autonomy of... |
| NCT00678626 | PHASE2 | WITHDRAWN | 0 | A Randomized Phase 2, Open-Label Study Of CP-751,871 In Combination With Docetax... |
| NCT06234137 | NA | RECRUITING | 154 | A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carbop... |
| NCT02125019 | N/A | COMPLETED | 62 | Longitudinal Evaluation of Taxane Induced Neuropathy in Early Stage Breast Cance... |
| NCT03588091 | PHASE3 | COMPLETED | 355 | A Randomized, Muticenter Double-blind Phase III Study of Neoadjuvant Pyrotinib P... |
| NCT02071862 | PHASE1 | COMPLETED | 210 | Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase... |
| NCT00311636 | PHASE3 | COMPLETED | 280 | Prevention of Chemotherapy-induced Menopause by Temporary Ovarian Suppression Wi... |
| NCT00471432 | PHASE1 | COMPLETED | 40 | A Phase I Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-... |
| NCT00006104 | PHASE2 | COMPLETED | 46 | A Multi-Institutional Phase II Pilot Trial With Weekly Docetaxel and Herceptin a... |
| NCT00535509 | NA | COMPLETED | 285 | Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women... |
| NCT00539968 | PHASE1, PHASE2 | TERMINATED | 5 | An Open-Label, Two-Part Study to Determine the Safety, Tolerability, and Activit... |
| NCT00193115 | PHASE2 | COMPLETED | 32 | Phase II Pilot Trial of Dose-Dense Docetaxel Followed by Doxorubicin Plus Cyclop... |
| NCT05301010 | PHASE3 | COMPLETED | 128 | Randomized, Single-blind, Multicenter, Parallel Group Clinical Trial to Assess E... |
| NCT01583426 | PHASE3 | COMPLETED | 1229 | A Randomized Phase III Trial Comparing Nanoparticle-based Paclitaxel With Solven... |
| NCT01094184 | PHASE4 | COMPLETED | 49 | Open-Label Study of Bevacizumab (Avastin®) and Taxane Monotherapy for the First-... |
| NCT02897050 | PHASE2 | SUSPENDED | 170 | Phase II Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed b... |
| NCT00887536 | PHASE3 | COMPLETED | 1613 | A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to T... |
| NCT02225652 | PHASE2 | COMPLETED | 11 | A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclo... |
| NCT02624973 | PHASE2 | ACTIVE_NOT_RECRUITING | 200 | PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial |
| NCT00645866 | PHASE2 | COMPLETED | 47 | A Neo-Adjuvant Study of Sequential Epirubicin and Docetaxel in Combination With ... |
| NCT01275677 | PHASE3 | COMPLETED | 3270 | A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (S... |
| NCT00258375 | PHASE2 | COMPLETED | 15 | A Phase II Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX... |
| NCT03170960 | PHASE1 | ACTIVE_NOT_RECRUITING | 914 | A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or i... |
| NCT02003209 | PHASE3 | COMPLETED | 315 | A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Pa... |
| NCT00769470 | PHASE2 | COMPLETED | 18 | A Multicenter, Open Label, Randomized Phase II Trial of Presurgical Treatment Wi... |
| NCT00431080 | PHASE3 | COMPLETED | 478 | A Multicenter Randomized Study Comparing the Dose Dense, G-CSF-Supported Sequent... |
| NCT05302336 | PHASE4 | UNKNOWN | 402 | A Randomized Controlled Study of AC (Doxorubicin Hydrochloride Liposome/Cyclopho... |
| NCT04931823 | PHASE1 | ACTIVE_NOT_RECRUITING | 126 | A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability,... |
| NCT00398489 | PHASE2 | UNKNOWN | 94 | Evaluation of Response Rate to Pre-Operative Docetaxel + Herceptin Study Part A ... |
| NCT00039520 | PHASE2 | COMPLETED | 10 | A Phase II Trial Of Exisulind With Docetaxel In Patients With Metastatic Adenoca... |
| NCT02413320 | PHASE2 | COMPLETED | 101 | Randomized Open Label Phase II Trial of Neoadjuvant Carboplatin Plus Docetaxel o... |
| NCT00950300 | PHASE3 | COMPLETED | 596 | A Phase III, Randomized Open-Label Study to Compare the Pharmacokinetics, Effica... |
| NCT00665457 | PHASE2 | TERMINATED | 3 | Neoadjuvant Therapy and Biomarker Analysis of Stage II and III Breast Cancer Wit... |
| NCT00118053 | PHASE2 | TERMINATED | 5 | A Phase II Trial of Taxotere, Carboplatin and Herceptin in Locally Advanced or I... |
| NCT03201861 | PHASE3 | RECRUITING | 762 | Phase 3 Study of Weekly Paclitaxel in Combination With Cisplatin as Adjuvant Che... |
| NCT01503905 | NA | UNKNOWN | 600 | Comparison of the Effectiveness of Neoadjuvant Chemotherapy and the Outcomes Ass... |
相關文獻
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 28398846 | 2017 | Article | Journal of clinical oncology : | Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/... |
| 7595719 | 1995 | Article | Journal of clinical oncology : | Docetaxel. |
| 27997437 | 2017 | Article | Anti-cancer drugs | Association between adjuvant docetaxel-based chemotherapy and breast cancer-rela... |
| 9282422 | 1997 | Article | Drug and therapeutics bulletin | Paclitaxel and docetaxel in breast and ovarian cancer. |
| 25073898 | 2014 | Article | World journal of surgical onco | Breast carcinoma with choriocarcinomatous features: a case report and review of ... |
| 16020974 | 2005 | Article | Oncology | Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast c... |
| 9364543 | 1997 | Article | Oncology (Williston Park, N.Y. | Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cel... |
| 26874836 | 2017 | Article | Breast cancer (Tokyo, Japan) | Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER... |
| 37584416 | 2023 | Article | The Kaohsiung journal of medic | FTO-mediated epigenetic upregulation of LINC01559 confers cell resistance to doc... |
| 9252781 | 1997 | Article | Dermatology (Basel, Switzerlan | Docetaxel-induced subungual hemorrhage. |
| 12714881 | 2003 | Article | American journal of clinical o | Biweekly docetaxel and vinorelbine in anthracycline-resistant metastatic breast ... |
| 19755993 | 2009 | Article | British journal of cancer | Gene expression profile and response to trastuzumab-docetaxel-based treatment in... |
| 10791395 | 2000 | Article | Lancet (London, England) | The taxanes: an update. |
| 23693018 | 2013 | Article | BMC cancer | Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy ... |
| 24347519 | 2014 | Article | Annals of oncology : official | Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment f... |
| 15074734 | 2004 | Article | Clinical oncology (Royal Colle | Trastuzumab and docetaxel for metastatic breast cancer: an experience from a can... |
| 22105826 | 2012 | Article | Journal of clinical oncology : | Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early bre... |
| 36736488 | 2023 | Article | Chemico-biological interaction | The prognostic gene CRABP2 affects drug sensitivity by regulating docetaxel-indu... |
| 28661759 | 2017 | Article | Journal of clinical oncology : | Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP... |
| 15858439 | 2005 | Article | Breast cancer (Tokyo, Japan) | Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluor... |
2. Ewing sarcoma L2 99.90%
臨床試驗（13 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT00014456 | PHASE1 | COMPLETED | 35 | A Dose-Escalation Trial Of The Combination Of Docetaxel, Gemcitabine And Filgras... |
| NCT04183062 | PHASE2 | WITHDRAWN | 0 | A Phase 2 Study of the Safety and Efficacy of BIO-11006 in the Treatment of Recu... |
| NCT06669013 | PHASE3 | RECRUITING | 40 | A Randomized, Multicenter, Open-label Phase III Study of Dinutuximab Beta With I... |
| NCT02511132 | PHASE2 | COMPLETED | 22 | A 2-part Trial Comparing Overall Survival of Patients With Metastatic Ewing's Sa... |
| NCT00049296 | PHASE1 | COMPLETED | 26 | Phase I Pharmacokinetic Trial of Thalidomide and Docetaxel: A Regimen Based on A... |
| NCT00073983 | PHASE2 | COMPLETED | 54 | Phase II Study Of Sequential Gemcitabine Followed By Docetaxel For Recurrent Ewi... |
| NCT01696669 | PHASE2 | COMPLETED | 43 | Phase 2, Open-label, Uncontrolled, Multicenter and Prospective Study of Intensiv... |
| NCT05116800 | PHASE2 | WITHDRAWN | 0 | A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibito... |
| NCT03491371 | NA | COMPLETED | 56 | The Effectivity and Toxicity of Methylsulfonic Apatinib for Extensively Pre-trea... |
| NCT03449901 | PHASE2 | COMPLETED | 98 | A Phase II Trial of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for... |
| NCT05999994 | PHASE2 | RECRUITING | 105 | CAMPFIRE: Children's and Young Adult Master Protocol for Innovative Pediatric Re... |
| NCT05634369 | PHASE1, PHASE2 | RECRUITING | 50 | A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK... |
| NCT00002825 | PHASE2 | COMPLETED | 20 | A PHASE II STUDY OF DOCETAXEL (TAXOTERE) (NSC# 628503) IN CHILDREN WITH RECURREN... |
相關文獻（20 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 28787430 | 2017 | Article | British journal of cancer | GEIS-21: a multicentric phase II study of intensive chemotherapy including gemci... |
| 25164234 | 2014 | Article | BMC cancer | A study of docetaxel and irinotecan in children and young adults with recurrent ... |
| 35023660 | 2021 | Article | The Turkish journal of pediatr | Primary spinal multifocal intradural-extramedullary Ewing sarcoma in children: p... |
| 32386107 | 2020 | Article | Pediatric blood & cancer | Phase II trial of gemcitabine and nab-paclitaxel in patients with recurrent Ewin... |
| 28221727 | 2017 | Article | Pediatric blood & cancer | Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescen... |
| 36890471 | 2023 | Article | BMC cancer | Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a... |
| 22302783 | 2012 | Article | Pediatric blood & cancer | Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory ... |
| 18484657 | 2008 | Article | Cancer | Combination of gemcitabine and docetaxel in the treatment of children and young ... |
| 22363068 | 2012 | Article | The oncologist | Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewi... |
| 15117993 | 2004 | Article | Journal of clinical oncology : | Laboratory and clinical evidence of synergistic cytotoxicity of sequential treat... |
| 29262551 | 2017 | Article | Oncotarget | The combination of temozolomide-irinotecan regresses a doxorubicin-resistant pat... |
| 19727011 | 2009 | Article | Journal of pediatric hematolog | Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetax... |
| 34496122 | 2021 | Article | Pediatric blood & cancer | Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on coope... |
| 34974029 | 2022 | Article | Journal of controlled release | SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas. |
| 41488266 | 2025 | Article | Cureus | Recurrent Ewing's Sarcoma of the Chest Wall in an Adolescent Male Patient: A Com... |
| 20132000 | 2010 | Article | Expert review of anticancer th | Role of chemotherapy in the management of soft tissue sarcomas. |
| 21795832 | 2011 | Article | Hinyokika kiyo. Acta urologica | [Retroperitoneal extraskeletal Ewing'ｓ sarcoma difficult to differentiate from a... |
| 39055564 | 2024 | Article | Frontiers in oncology | Case report: Metastatic refractory undifferentiated small round-cell sarcoma suc... |
| 26154614 | 2015 | Article | Pediatric blood & cancer | Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetax... |
| 24753077 | 2014 | Article | Pediatric blood & cancer | Preclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of... |
3. well-differentiated fetal adenocarcinoma of the lung L4 99.84%
相關文獻（1 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 23750171 | 2013 | Article | Tuberculosis and respiratory d | A case of locally advanced well-differentiated fetal adenocarcinoma of the lung ... |
4. small cell lung carcinoma L1 99.83%
臨床試驗（50 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT00903292 | NA | UNKNOWN | 52 | Tailored Second Line Treatment by EGFR Mutation in Patients With Advanced Lung A... |
| NCT03304093 | PHASE2 | COMPLETED | 30 | Immunotherapy by Nivolumab After Prior Chemotherapy for HIV+ Patients With Advan... |
| NCT00051974 | PHASE2 | COMPLETED | 155 | A Randomized, Multicenter, Open-Label, Phase 2 Study of VELCADE Alone or VELCADE... |
| NCT01891123 | NA | UNKNOWN | 300 | An Open-label Randomized Clinical Trial to Compare the Toxicities and Efficacy o... |
| NCT04747470 | PHASE1 | TERMINATED | 13 | A Phase 1b Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacok... |
| NCT02740985 | PHASE1 | COMPLETED | 313 | A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmac... |
| NCT00622349 | PHASE3 | COMPLETED | 707 | A Phase III Randomised Study Comparing Three Combination Chemotherapy Regimens i... |
| NCT01798485 | PHASE3 | TERMINATED | 696 | A Randomized, Phase 3 Study of Ganetespib in Combination With Docetaxel Versus D... |
| NCT00114192 | PHASE2 | COMPLETED | 37 | Phase II Study of Docetaxel and Thalidomide as a Second-Line Treatment for Non-S... |
| NCT01015963 | N/A | COMPLETED | 69 | A Study of the Docetaxel Pharmacodynamics and Polymorphisms in ABCC2 and SLC01B3... |
| NCT00064636 | PHASE1 | TERMINATED | 46 | A Phase I, Open Label, Dose Escalation Study of PS-341 Plus Docetaxel in Treatme... |
| NCT00095225 | PHASE2 | COMPLETED | 122 | A Phase II, Multicenter, Randomized Clinical Trial to Evaluate the Efficacy and ... |
| NCT02876081 | PHASE2 | WITHDRAWN | 0 | Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With... |
| NCT06532032 | PHASE1, PHASE2 | ACTIVE_NOT_RECRUITING | 12 | A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxe... |
| NCT00862134 | PHASE2 | TERMINATED | 42 | A Randomized Phase II, Multi-Center, Open-Label Trial of PR104 and Docetaxel in ... |
| NCT01138163 | PHASE2 | COMPLETED | 121 | A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus... |
| NCT02766335 | PHASE2, PHASE3 | COMPLETED | 116 | A Phase II Study of MEDI4736 for Previously Treated Patients With Stage IV Squam... |
| NCT02058433 | PHASE3 | UNKNOWN | 140 | Phase 3, Randomized, Open-label Study of the Safety of Individual Paclitaxel Dos... |
| NCT01348126 | PHASE2, PHASE3 | TERMINATED | 385 | A Randomized, Phase IIB/III Study of Ganetespib (STA-9090) in Combination With D... |
| NCT02959749 | PHASE2, PHASE3 | COMPLETED | 147 | Phase III Study of Osimertinib or Docetaxel-bevacizumab as Third-line Treatment ... |
| NCT00499109 | PHASE3 | COMPLETED | 275 | Randomized Phase III Multicenter Trial of RRM1 & ERCC1 Directed Customized Chemo... |
| NCT00686985 | PHASE2 | COMPLETED | 50 | A Phase II Study of Docetaxel - Carboplatin As Second Line Treatment in Patients... |
| NCT02889666 | PHASE1 | RECRUITING | 500 | A Multi-Center and Randomized Control Trial of Cisplatin, Carboplatin, Oxaliplat... |
| NCT06266299 | PHASE1 | RECRUITING | 101 | A Phase 1, Multicenter, Open-label, Dose-escalation Study Evaluating the Safety ... |
| NCT00092001 | PHASE2 | COMPLETED | 111 | A Phase 2 Efficacy And Safety Study Of SU011248 In Patients With Metastatic Non-... |
| NCT01750281 | PHASE2 | COMPLETED | 212 | A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Eff... |
| NCT03976375 | PHASE3 | COMPLETED | 422 | A Phase 3, Multicenter, Randomized, Open-label Trial to Compare the Efficacy and... |
| NCT03735264 | PHASE2 | UNKNOWN | 46 | Anlotinib Combined With Docetaxel For Advanced Non-Small Cell Lung Cancer After ... |
| NCT00741221 | PHASE2 | COMPLETED | 50 | Pemetrexed Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell... |
| NCT01802021 | PHASE2, PHASE3 | UNKNOWN | 120 | Efficacy Study of Chinese Medicine on Modulating Immune Alterations in Advanced ... |
| NCT06868732 | PHASE1 | NOT_YET_RECRUITING | 288 | Evaluation of JSKN016 Combination Therapy in Subjects with Advanced Non-Small Ce... |
| NCT01204099 | PHASE1, PHASE2 | COMPLETED | 223 | Phase 1/2 Study of PX-866 and Docetaxel in Patients With Solid Tumors |
| NCT03358875 | PHASE3 | COMPLETED | 805 | A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy... |
| NCT00003900 | PHASE2 | COMPLETED | 48 | A Phase II Study of Irinotecan (CPT-11) and Docetaxel (Taxotere) in Patients Wit... |
| NCT00020709 | PHASE3 | COMPLETED | 840 | A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With Consolidation Docetax... |
| NCT03407300 | PHASE2 | UNKNOWN | 80 | A Prospective, Randomized Clinical Study of Safety and Efficacy by Using Docetax... |
| NCT00536107 | PHASE4 | TERMINATED | 14 | A Randomized/Open Label/Parallel Group/Multicenter/Phase IV Study to Assess Safe... |
| NCT05089734 | PHASE3 | ACTIVE_NOT_RECRUITING | 603 | Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govite... |
| NCT02439346 | PHASE1 | TERMINATED | 15 | An Open-label, Non-randomized, Multicenter Phase I Study to Characterize the Saf... |
| NCT00026156 | PHASE2 | COMPLETED | 125 | Phase II Trial of Sequential Vinorelbine and Docetaxel in Advanced Non-Small Cel... |
| NCT00118131 | PHASE2 | TERMINATED | 49 | Phase II Study of Weekly Docetaxel Together With Weekly Cisplatin in Chemotherap... |
| NCT05714553 | PHASE1, PHASE2 | TERMINATED | 19 | A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion ... |
| NCT03509584 | PHASE1 | TERMINATED | 6 | Phase I Multicenter Trial Combining Nivolumab, Alone or With Ipilimumab, Plus Hy... |
| NCT00059943 | PHASE2 | COMPLETED | N/A | Pharmacokinetics of Weekly Docetaxel in Patients Age 65 and Older With Metastati... |
| NCT02831491 | PHASE2 | WITHDRAWN | 0 | A Single-Arm, Phase 2 Study of Ramucirumab in Combination With Weekly Docetaxel ... |
| NCT00148291 | PHASE3 | COMPLETED | 180 | Phase III Study of Docetaxel Vs Vinorelbine in Elderly Patients With Advanced No... |
| NCT04062708 | PHASE2 | ACTIVE_NOT_RECRUITING | 38 | CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable... |
| NCT02780778 | PHASE2, PHASE3 | UNKNOWN | 20 | Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squa... |
| NCT00293085 | PHASE2 | COMPLETED | 37 | An Open, Randomized, Multicentre, Phase II Pilot Study of Docetaxel and Cisplati... |
| NCT00014456 | PHASE1 | COMPLETED | 35 | A Dose-Escalation Trial Of The Combination Of Docetaxel, Gemcitabine And Filgras... |
相關文獻（20 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 37196428 | 2023 | Article | Journal of clinical oncology : | Flashback Foreword: Docetaxel Versus Best Supportive Care in Non-Small-Cell Lung... |
| 36773042 | 2023 | Article | European journal of clinical p | Sequencing strategies with ramucirumab and docetaxel following prior treatments ... |
| 37945672 | 2023 | Article | Scientific reports | Detection of factors related to treatment reduction in docetaxel and ramucirumab... |
| 20038723 | 2010 | Article | Journal of clinical oncology : | Molecular predictors of outcome with gefitinib and docetaxel in previously treat... |
| 39434017 | 2024 | Article | BMC cancer | Effect of baseline anemia on the efficacy of docetaxel and ramucirumab for advan... |
| 32439358 | 2020 | Article | Cancer radiotherapie : journal | Outcomes of concurrent radiotherapy with weekly docetaxel and platinum-based che... |
| 40404206 | 2025 | Article | Journal for immunotherapy of c | Development and validation of a serum proteomic test for predicting patient outc... |
| 34403911 | 2021 | Article | Lung cancer (Amsterdam, Nether | Randomized phase III study of docetaxel versus docetaxel plus intercalated erlot... |
| 33982408 | 2021 | Article | Clinical and translational sci | Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase... |
| 31951770 | 2020 | Article | Journal of medical economics | Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatme... |
| 30913364 | 2019 | Article | Thoracic cancer | Efficacy of subsequent docetaxel +/- ramucirumab and S-1 after nivolumab for pat... |
| 31179803 | 2019 | Article | The Journal of international m | A phase II study of the combination of docetaxel and bevacizumab for previously ... |
| 30602615 | 2019 | Article | The oncologist | An Open-Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Ad... |
| 40679002 | 2025 | Article | Pakistan journal of pharmaceut | Comparison of anlotinib combined with docetaxel versus single docetaxel as secon... |
| 31631526 | 2019 | Article | Thoracic cancer | Retrospective cohort study on the safety and efficacy of docetaxel in Japanese n... |
| 32464632 | 2020 | Article | Oncology | The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung ... |
| 41373437 | 2025 | Article | International journal of molec | Docetaxel and Gemcitabine Modulate Cellular Effects and Long Non-Coding RNA Prof... |
| 32924677 | 2020 | Article | Journal of microencapsulation | Fabrication, optimisation and in vitro evaluation of docetaxel and curcumin Co-l... |
| 27912835 | 2017 | Article | Hematology/oncology clinics of | Second-Line Chemotherapy and Beyond for Non-Small Cell Lung Cancer. |
| 34488513 | 2021 | Article | Expert review of clinical phar | Factors affecting the efficacy and safety of docetaxel combined with platinum in... |
5. primary pulmonary lymphoma L1 99.83%
臨床試驗（8 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT03884556 | PHASE1 | COMPLETED | 56 | Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination W... |
| NCT05094336 | PHASE1, PHASE2 | ACTIVE_NOT_RECRUITING | 329 | A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Phar... |
| NCT06074588 | PHASE3 | RECRUITING | 556 | A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or... |
| NCT03611738 | PHASE1 | ACTIVE_NOT_RECRUITING | 21 | Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCL... |
| NCT00049296 | PHASE1 | COMPLETED | 26 | Phase I Pharmacokinetic Trial of Thalidomide and Docetaxel: A Regimen Based on A... |
| NCT04800146 | N/A | COMPLETED | 177 | A Prospective Observational Study on the Immune-response to SARS-CoV-2 Vaccinati... |
| NCT02604342 | PHASE3 | COMPLETED | 119 | Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Pemetre... |
| NCT03786692 | PHASE2 | RECRUITING | 117 | TH-138: Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, Wit... |
相關文獻（18 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 23724913 | 2013 | Article | The New England journal of med | Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. |
| 37593227 | 2023 | Article | EClinicalMedicine | AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy i... |
| 19879424 | 2009 | Article | Advances in cancer research | Clusterin and chemoresistance. |
| 32529467 | 2020 | Article | Investigational new drugs | A randomized, double-blind, placebo-controlled study of B-cell lymphoma 2 homolo... |
| 31023244 | 2019 | Article | BMC cancer | Comparative survival benefit of currently licensed second or third line treatmen... |
| 36725772 | 2023 | Article | Thoracic cancer | Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination ... |
| 19816079 | 2009 | Article | Onkologie | Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analy... |
| 15812395 | 2005 | Article | Biology of blood and marrow tr | Phase I and pharmacokinetic study of docetaxel combined with melphalan and carbo... |
| 35042152 | 2022 | Article | ESMO open | Final efficacy and safety data, and exploratory molecular profiling from the pha... |
| 30061946 | 2018 | Article | Oncology letters | CCL2 influences the sensitivity of lung cancer A549 cells to docetaxel. |
| 29668860 | 2018 | Article | Annals of oncology : official | Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinas... |
| 26446239 | 2015 | Article | The oncologist | U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatmen... |
| 24327273 | 2014 | Article | Clinical cancer research : an | Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-... |
| 28602779 | 2017 | Article | The Lancet. Oncology | Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lun... |
| 32160733 | 2020 | Article | Hinyokika kiyo. Acta urologica | [A Case of Primary Central Nervous System Lymphoma that Developed during the Tre... |
| 41360030 | 2026 | Article | Lung cancer (Amsterdam, Nether | Long-term survival with PD-1/PD-L1 inhibitors plus platinum-based chemotherapy v... |
| 25170012 | 2014 | Article | The oncologist | FDA approval summary: crizotinib for the treatment of metastatic non-small cell ... |
| 32676310 | 2020 | Article | Translational lung cancer rese | Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab... |
6. botryoid-type embryonal rhabdomyosarcoma of the vagina L5 99.80%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
7. pulmonary blastoma L4 99.80%
相關文獻（3 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 38835107 | 2024 | Article | The Journal of international m | Pulmonary blastoma with a good prognosis: a case report and review of the litera... |
| 41626175 | 2025 | Article | Frontiers in oncology | Exceptional long-term survival in an adult with advanced classic biphasic pulmon... |
| 23750171 | 2013 | Article | Tuberculosis and respiratory d | A case of locally advanced well-differentiated fetal adenocarcinoma of the lung ... |
8. rhabdomyosarcoma (disease) L2 99.79%
臨床試驗（6 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT04906876 | PHASE2 | WITHDRAWN | 0 | A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibito... |
| NCT06669013 | PHASE3 | RECRUITING | 40 | A Randomized, Multicenter, Open-label Phase III Study of Dinutuximab Beta With I... |
| NCT05116800 | PHASE2 | WITHDRAWN | 0 | A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibito... |
| NCT03524898 | PHASE1, PHASE2 | TERMINATED | 39 | NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma. A Multic... |
| NCT05634369 | PHASE1, PHASE2 | RECRUITING | 50 | A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK... |
| NCT00002825 | PHASE2 | COMPLETED | 20 | A PHASE II STUDY OF DOCETAXEL (TAXOTERE) (NSC# 628503) IN CHILDREN WITH RECURREN... |
相關文獻（9 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 22302783 | 2012 | Article | Pediatric blood & cancer | Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory ... |
| 37422615 | 2023 | Article | BMC cancer | A phase II study of gemcitabine and docetaxel combination in relapsed metastatic... |
| 36119541 | 2022 | Article | Frontiers in oncology | Embryonic esophageal rhabdomyosarcoma in an adult male: A case report and litera... |
| 35529801 | 2022 | Article | Journal of kidney cancer and V | Primary Rhabdomyosarcoma of Kidney with Local Recurrence and Liver Metastasis in... |
| 36890471 | 2023 | Article | BMC cancer | Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a... |
| 20132000 | 2010 | Article | Expert review of anticancer th | Role of chemotherapy in the management of soft tissue sarcomas. |
| 14585225 | 2003 | Article | Current treatment options in o | New therapeutic strategies for soft tissue sarcomas. |
| 40755557 | 2025 | Article | Acta medica Philippina | Vulvar Rhabdomyosarcoma in an Adult Female Patient: A Case Report and Review of ... |
| 16532433 | 2006 | Article | Cancer | Phase II investigation of docetaxel in pediatric patients with recurrent solid t... |
9. embryonal extrahepatic bile duct rhabdomyosarcoma L5 99.76%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
10. parameningeal embryonal rhabdomyosarcoma L5 99.76%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
資料來源：DDInter 2.0（原文內容請參閱該網站）
**葡萄柚汁** 🟢 Minor
- 影響：影響藥物代謝。可能增加藥物血中濃度。
- 建議：避免大量攝取。需監測療效或不良反應。避免食用葡萄柚或葡萄柚汁。
### 藥物-草藥交互作用 (DHI)
**聖約翰草（貫葉連翹）** 🔴 Major
- 影響：聖約翰草降低化療藥物療效
- 建議：化療期間禁用所有草藥補充品
### 藥物-疾病注意事項 (DDSI)
資料來源：DDInter 2.0（原文內容請參閱該網站）
**Alcoholism** 🟡 Moderate
- 需定期監測。
**Paresthesia** 🟡 Moderate
- 可能有嚴重不良反應。出現症狀時應考慮停藥。
**Infections** 🟢 Minor
- 本藥物在此情況下禁用。需定期監測。風險包括：骨髓抑制、感染。
**Edema** 🟢 Minor
- 可能有嚴重不良反應。
**Eye Diseases** 🟢 Minor
- 必要時應停止治療。
**肝臟疾病** 🟢 Minor
- 不應使用本藥物。可能有致命風險。
**Bone Marrow Failure Disorders** 🟢 Minor
- 本藥物在此情況下禁用。風險包括：骨髓抑制、感染、血栓、貧血。可能有嚴重不良反應。
## 結論與下一步
**決策：Proceed**
**理由：**
Docetaxel 在女性乳腺癌的臨床應用已有大量 Phase 3 試驗支持，療效證據充分，
且作用機轉與預測適應症高度相關。
**若要推進需要：**
- 針對特定乳癌亞型的精準治療方案優化
- 減少周邊神經病變等長期毒性的策略研究
---
## 相關藥物報告
- [Temozolomide](/drugs/temozolomide/) - 證據等級 L1
- [Anastrozole](/drugs/anastrozole/) - 證據等級 L1
- [Icatibant](/drugs/icatibant/) - 證據等級 L1
- [Naftifine](/drugs/naftifine/) - 證據等級 L1
- [Ipratropium](/drugs/ipratropium/) - 證據等級 L1
---
用 AI 幫我深入分析
想進一步了解這個藥物的老藥新用潛力嗎？點擊下方按鈕，直接開啟 AI 助手進行分析。
Claude：點擊後會複製提問並開啟新視窗，請按 Ctrl+V（Mac: Cmd+V）貼上
ChatGPT：點擊後直接開啟並自動帶入提問
免責聲明
本報告僅供學術研究參考，不構成醫療建議。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
最後審核：2026-02-20 | 審核者：TwTxGNN Research Team
本報告僅供學術研究參考，不構成醫療建議。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
最後審核：2026-02-20 | 審核者：TwTxGNN Research Team
歡迎分享您對本報告的看法、補充資訊或提出問題。討論內容會同步到 GitHub Discussions。 需要 GitHub 帳號才能留言。